Compare ELA & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELA | AMRN |
|---|---|---|
| Founded | 1965 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.7M | 304.3M |
| IPO Year | 1995 | 1998 |
| Metric | ELA | AMRN |
|---|---|---|
| Price | $24.25 | $15.01 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 2 | 1 |
| Target Price | ★ $16.50 | $12.00 |
| AVG Volume (30 Days) | ★ 86.4K | 80.6K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 115.38 | 55.00 |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $241,021,362.00 | $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.54 | $1.26 |
| P/E Ratio | $72.21 | ★ N/A |
| Revenue Growth | 33.62 | ★ 39.22 |
| 52 Week Low | $5.33 | $11.03 |
| 52 Week High | $25.09 | $20.90 |
| Indicator | ELA | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 77.64 | 56.14 |
| Support Level | $11.34 | $14.65 |
| Resistance Level | N/A | $15.43 |
| Average True Range (ATR) | 1.49 | 0.67 |
| MACD | 0.66 | 0.10 |
| Stochastic Oscillator | 74.69 | 75.57 |
Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. It operates through two segments, Consumer and Commercial Services. The Consumer segment, which generates key revenue for the company, predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins, and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.